Blood Cancer

In the last 2 hours

Making chemotherapy for Hodgkin lymphoma kinder to patients Cambridge University Hospitals (Press Release)23:36 11-Dec-24

In the last 4 hours

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML OncLive22:23 11-Dec-24

Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data American Journal of Managed Care21:26 11-Dec-24

In the last 6 hours

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma OncLive21:02 11-Dec-24

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study Medpage Today20:27 11-Dec-24

In the last 8 hours

'Golden Bachelor' star Gerry Turner shares cancer diagnosis ABC7 / WLS-TV18:53 11-Dec-24

Cilta-cel Leads to Prolonged Progression-Free Survival in Multiple Myeloma American Journal of Managed Care17:42 11-Dec-24

Yesterday

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma OncLive16:38 11-Dec-24

Sussex hospital wins award after helping Haywards Heath grandfather with blood cancer who… SussexWorld15:39 11-Dec-24

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma Medpage Today14:01 11-Dec-24

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma News-Medical.Net13:23 11-Dec-24

ASH 2024: J&J’s Tecvayli shows promise in transplant-eligible NDMM patient Pharmaceutical Technology10:27 11-Dec-24

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial News-Medical.Net04:25 11-Dec-24

Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug? Stockhead02:16 11-Dec-24

In the last 7 days

Footy legend Anthony Rocca's huge news after shock cancer diagnosis MailOnline23:18 10-Dec-24

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma OncLive22:50 10-Dec-24

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma OncLive22:50 10-Dec-24

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL OncLive22:40 10-Dec-24

Filling Out the Roadmap for Faster Drug Approvals Newswise (Press Release)21:50 10-Dec-24

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL OncLive20:58 10-Dec-24

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM OncLive20:48 10-Dec-24

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma OncLive20:07 10-Dec-24

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma OncLive19:47 10-Dec-24

Research shows new treatment could delay cancer progression in patients with high-risk smoldering multiple myeloma Newswise (Press Release)19:11 10-Dec-24

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL OncLive18:26 10-Dec-24

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma Medpage Today18:19 10-Dec-24

Year in Review: Chronic Lymphocytic Leukemia Medpage Today17:07 10-Dec-24

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma OncLive16:24 10-Dec-24

Adding Tafasitamab to Standard Follicular Lyphoma Regimen Boosts PFS 57%, Study Finds American Journal of Managed Care15:45 10-Dec-24

Stem Cell Transplant Offers No Additional Benefit for Patients with Mantle Cell Lymphoma in… PR Newswire (Press Release)15:35 10-Dec-24

Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with… PR Newswire (Press Release)15:35 10-Dec-24

Ash 2024: Car T-cell therapy demonstrates durable benefit in lymphoma European Pharmaceutical Review15:24 10-Dec-24

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2… PR Newswire (Press Release)14:37 10-Dec-24

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor… PR Newswire (Press Release)12:51 10-Dec-24

'We always said that Fred would change the world': Dunchurch teen’s legacy helps childhood… Warwickshire World12:45 10-Dec-24

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma PMLiVE12:22 10-Dec-24

ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders ecancer12:10 10-Dec-24

ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or… ecancer11:50 10-Dec-24

ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in… ecancer11:39 10-Dec-24

ASH 2024: Daratumumab cuts risk of progression by half in smouldering multiple myeloma ecancer11:39 10-Dec-24

ASH 2024: Could venetoclax improve outcomes of CAR T for patients with resistant B-cell… ecancer11:29 10-Dec-24

Exploring Socioeconomic Disparities in Diffuse Large B-Cell Lymphoma Survival in Germany: A Nationwide Study Behavioural and Social Sciences at Nature Research10:52 10-Dec-24

ASH: Blenrep ups survival by 42% in multiple myeloma trial pharmaphorum10:29 10-Dec-24

ASH 2024 - Resistance training can reduce fatigue, pain in multiple myeloma patients ecancer09:38 10-Dec-24

ASH 2024 - High-fibre diet may slow disease progression to multiple myeloma ecancer09:38 10-Dec-24

ASH 2024: Preclinical study shows targeted drug strengthens the power of CAR T-cell therapy in… ecancer09:18 10-Dec-24

Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy… Nature.com08:44 10-Dec-24

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve… GlobeNewswire (Press Release)06:05 10-Dec-24

EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH)… Newswise (Press Release)02:03 10-Dec-24

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes… PR Newswire (Press Release)02:00 10-Dec-24

ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma Pharmacy Times01:30 10-Dec-24

ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma Pharmacy Times01:00 10-Dec-24

Novel drug combination shows promise for CLL treatment News-Medical.Net00:47 10-Dec-24

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with… GlobeNewswire (Press Release)00:39 10-Dec-24

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma OncLive00:17 10-Dec-24

Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma OncLive00:07 10-Dec-24

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers News-Medical.Net00:07 10-Dec-24

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of… GlobeNewswire (Press Release)22:47 9-Dec-24

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated… PR Newswire (Press Release)22:46 9-Dec-24

Epcoritamab Offers Durable Results in Relapsed B-Cell Lymphoma American Journal of Managed Care21:26 9-Dec-24

Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple… Pharmacy Times20:46 9-Dec-24

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma OncLive19:32 9-Dec-24

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients GlobeNewswire (Press Release)19:13 9-Dec-24

Anticancer drugs could make immunotherapies more effective ScienceDaily19:04 9-Dec-24

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic… OncLive18:41 9-Dec-24

Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after… GlaxoSmithKline (Press Release)18:35 9-Dec-24

Phase 3 GMMG-HD7 Trial: Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma Pharmacy Times18:33 9-Dec-24

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable… PR Newswire (Press Release)17:09 9-Dec-24

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and… PR Newswire (Press Release)17:09 9-Dec-24

Daratumumab Significantly Delays Smoldering Multiple Myeloma Progression American Journal of Managed Care16:41 9-Dec-24

High-fibre diet may slow disease progression to multiple myeloma ecancer16:20 9-Dec-24

Treatment of Smoldering Myeloma Cuts Progression Rate in Half Medpage Today16:10 9-Dec-24

Resistance training can reduce fatigue, pain in multiple myeloma patients ecancer16:00 9-Dec-24

Repurposed drug has promising efficacy in non-small cell lung cancer Newswise (Press Release)15:43 9-Dec-24

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma OncLive15:17 9-Dec-24

High-Fiber Diet May Ward Off Blood Cancer NewsMax15:12 9-Dec-24

Adaptive unveils data of MRD assessment test in blood cancer treatment Verdict Medical Devices15:05 9-Dec-24

Breakthrough treatment improves survival rates for children with B-ALL News-Medical.Net13:55 9-Dec-24

Second generation CAR-T shows promise for ALL British Society for Haematology11:38 9-Dec-24

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma pharmaphorum11:36 9-Dec-24

High-Fiber Diet May Prevent a Blood Cancer in People at High Risk HealthDay11:03 9-Dec-24

BIA announces Blood Cancer UK as charity partner of the year UK BioIndustry Association (Press Release)10:27 9-Dec-24

Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma … PR Newswire (Press Release)10:01 9-Dec-24

DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed… GlobeNewswire (Press Release)08:00 9-Dec-24

Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma GlaxoSmithKline (Press Release)07:13 9-Dec-24

ASH 2024: Rapid Uptake of Bispecific Antibodies for R/R Multiple Myeloma Observed in Community Oncology Settings Pharmacy Times01:56 9-Dec-24

ASH 2024: New Treatments in Trial Pipeline Show Promising Survival Rates in R/R Multiple Myeloma Pharmacy Times01:56 9-Dec-24

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma OncLive22:42 8-Dec-24

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL OncLive21:41 8-Dec-24

Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows Newswise (Press Release)21:32 8-Dec-24

Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study Pharmacy Times21:32 8-Dec-24

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL OncLive21:11 8-Dec-24

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma Medpage Today19:40 8-Dec-24

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for… PR Newswire (Press Release)17:39 8-Dec-24

Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma Newswise (Press Release)17:39 8-Dec-24

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed… GlobeNewswire (Press Release)17:38 8-Dec-24

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated… GlobeNewswire (Press Release)17:35 8-Dec-24

ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma Newswise (Press Release)17:08 8-Dec-24

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of… PR Newswire (Press Release)16:48 8-Dec-24

DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple… GlobeNewswire (Press Release)16:26 8-Dec-24

Lymphoma Immunotherapy Enhanced by Enzyme Inhibitor In Preclinical Model, Prompting Pilot Clinical Studies Genetic Engineering and Biotechnology News15:53 8-Dec-24

CAR T-cell therapy trials: How far has India reached? The Week14:27 8-Dec-24

ASH: Cilta-Cel Significantly Increases Minimum Residual Disease Negativity in Lenalidomide-Refractory Multiple Myeloma Pharmacy Times07:47 8-Dec-24

ASH Expert: Axi-Cel Treatment Causes Decreased Incidence, Severity of Toxicities in Large B-Cell Lymphoma Pharmacy Times07:17 8-Dec-24

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma OncLive02:43 8-Dec-24

Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias Newswise (Press Release)00:09 8-Dec-24

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of… AbbVie (Press Release)00:05 8-Dec-24

New study reveals a fiber diet may delay a type of blood cancer EurekAlert!21:07 7-Dec-24

Blinatumomab Plus Chemotherapy Improves DFS in Pediatric Patients With SR B-ALL Pharmacy Times17:13 7-Dec-24

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia Medpage Today15:09 7-Dec-24

New Research from Children’s Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly… Newswise (Press Release)15:09 7-Dec-24

Landmark Clinical Trial Results Offer New Hope for Kids with Acute Lymphoblastic Leukemia (ALL) PR Newswire (Press Release)15:08 7-Dec-24

Seattle Children's researchers greatly improve survival for children diagnosed with the most… PR Newswire (Press Release)15:08 7-Dec-24

Global clinical trial shows improved survival rates for common childhood leukemia EurekAlert!15:07 7-Dec-24

Blincyto® (Blinatumomab) Added To Chemotherapy Significantly Improves Survival In Newly Diagnosed Pediatric Patients… Amgen (Press Release)15:05 7-Dec-24

view more headlines

11 Dec 23:36

Blood Cancer

Cancer Top Stories

Health Top Stories

UK Top Stories

World Top Stories